Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 291

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 291
---
 to the Initial Shareholders and their affiliates. |     | APx could potentially have found a target that may have a more optimal risk/return profile than OmnigenicsAI. In this case, APx, its shareholders and its affiliates would stand to benefit more than in the business combination with OmnigenicsAI |

135

| Stakeholder                  |     | Benefits                                                                                                                                                                                                                                                                                                                                                                             |     | Detriments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Unaffiliated securityholders |     | If the market was to recognize the valuation and potential of OmnigenicsAI the share price may be expected to increase from the current redemption price of the Public Shares, which will benefit the Public Shareholders.                                                                                                                                                           
 Additionally, if the share price increases following the Business Combination, warrantholders may be able to exercise their warrants at an exercise price lower than the then-current share price.                                                                                                                                                                                   |     | For non-redeeming shareholders the risk is that the market will not support the valuation of OmnigenicsAI either as a result of a general market downturn or risks specific to OmnigenicsAI. In this case, the stock price may be reasonably expected to trade below the current redemption price of the Public Shares. If this scenario were to materialize, the Public Shareholders would have been better off redeeming rather than holding Company Shares post-business combination.                                                                                 |
| OmnigenicsAI and affiliates  |     | After the consummation of the Business Combination, the Company Shares are expected to be listed on Nasdaq. As a U.S. public company, OmnigenicsAI and therefore, OmnigenicsAI’s legacy stockholders, will enjoy enhanced visibility in the capital markets, which could help amplify the brand awareness of OmnigenicsAI and increase the revenue of OmnigenicsAI.                  
 In addition, OmnigenicsAI will be able to raise funds through the U.S. public capital markets, providing it with access to capital to execute its expansion and growth strategies.                                                                                                                                                                                                   
 Further, OmnigenicsAI’s legacy shareholders had (directly or indirectly) acquired their respective shares of OmnigenicsAI at a price lower than $10.00 per Company Share. To the extent that the Company Shares will trade above their per share acquisition price, legacy OmnigenicsAI stockholders will receive a positive return on their respective investments in OmnigenicsAI. 
 See also “Questions and Answers About the Business Combination and the Special Meeting — What interests do our Initial Shareholders, current officers, directors and advisors, and the